Bladder Cancer - KOL Insight

How are Keytruda and Padcev transforming bladder cancer treatment? What are the competitive dynamics surrounding Opdivo? How are Padcev's clinical trials and Adstiladrin's US launch impacting the field? KOLs provide an in-depth analysis of the current and future landscape of bladder cancer treatments with key insights on practice-changing clinical trials, emerging therapies, and the latest trends shaping the future of bladder cancer treatment.

Key brands covered in this report:

Companies:

Roche, AstraZeneca, Pfizer, Merck & Co., Bristol Myers Squibb, Altor BioScience, Gilead Sciences, Astellas, Johnson & Johnson Innovative Medicine, Exelixis, Ipsen, ImmunityBio, FKD Therapies, Ferring, CG Oncology, Theralase, CatalYM.

Key questions answered:

• What are the current treatments of choice for bladder cancer, and what attributes contribute to their preference?
• How do experts view approved checkpoint inhibitor therapies like Keytruda, Opdivo, and Bavencio?
• What are KOL perceptions of the Padcev-Keytruda combination?
• What could be the impact of subcutaneous formulations in treating bladder cancer?
• How will the bladder cancer treatment landscape evolve for each patient segment and line of therapy?
• Which patient characteristics influence treatment choice, and how are pipeline therapies likely to be used?
• Which key clinical trials have the greatest potential to impact prescribing trends?
• What efficacy and safety data will pipeline products need to show to gain regulatory approval and compete with current market leaders?